Hibiclens is a 4% chlorhexidine gluconate (CHG) solution for patient cleansing and skin antisepsis which has been trusted by hospitals and healthcare professionals for more than 40 years.
In numerous studies and publications, the incorporation of Hibiclens into a prevention strategy showed significant reductions in infection rates. These results include:
- Decreased difficile infections by 88%1
- 63% CLABSI reduction, 70.3% of which was from MBI-CLABSI improvement2
- Decrease in superficial SSls of 67%3
- Lowered methicillin-resistant Staphylococcus aureus (MRSAI) by 32%4
- Reduced vancomycin-resistant Ener ococcus (VREI) by 50%4
- 61% lower incidence of primary bloodstream infections5
Why Hibiclens is so effective
Chlorhexidine, the active ingredient in Hibiclens, is a broad-spectrum antiseptic skin cleanser that is proven effective against a wide range of bacteria, fungi, viruses and yeast. Washing with chlorhexidine kills bacteria by disrupting the cell membrane.
When used topically, chlorhexidine has the unique ability to bind to the proteins present in human tissues, including skin, with limited systemic or bodily absorption.6 Once it is bound to proteins, chlorhexidine releases slowly, allowing for a longer duration of antimicrobial action.
- 4% CHG begins to kill pathogens on contact7
- Washes clean, leaving a layer of chlorohexidine gluconate protection without sticky residue
- Continues killing 99% of pathogens for up to 24 hours8
- Results in a cumulative effect with repeat use, such as daily bathing
- Incorporates easily into a patient’s usual skin cleansing routine
When to use Hibiclens
Hibiclens 4% CHG solution is in a gentle, skin-cleaning base that can be used for:
- Daily patient bed baths as part of a horizontal infection prevention approach
- Pre-operative/post-operative showering and decolonization as part of surgical site infection prevention bundles
- Surgical hand scrubbing
- Personal hand washing
- Preoperative skin preparation
- Kimberly Candray, CIC, BS, MT(ASCP). A Bundled Approach to Clostridium difficile Infection Reduction, Infection Control Today, October 2018.
- May M. Riley, RN, MSN, et al. Central Line-Associated Bloodstream Infections and Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections: Results from a Quality-Improvement Project in a Hematology-Oncology Unit. APIC Poster Presentation, 2018.
- Robert Cima, MD, Eugene Dankbar, MS et al. Colorectal Surgery Surgical Site Infection Reduction Program: A National Surgical Quality Improvement Program Driven Multidisciplinary Single-Institution Experience, J Am College Surgery, Vol. 216, No. 1, January 2013.
- Climo, Michael W., et al. The Effect of Daily Bathing with Chlorhexidine on the Acquisition of Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococcus, and Healthcare-associated Bloddstream Infections: Results of a Quasi-experimental Multicenter Trial. Critical Care Medicine. 2009;37(6):1858-1865.
- Susan C. Bleasdale, MD, et al. Archives of Internal Medicine, Oct 22, 2007.
- World Health Organization. WHO Guidelines on hand Hygiene on Health Care. WHO, 2009.
- Paulson, Daryl S. Persistent and Residual Antimicrobial Effects: Are They Important in the Clinical Setting? Infection Control Today 2005; Vol 9. No 4.
- MBT Study No. 582-106, Study Protocol # 5220.127.116.11.12.